USDM Life Sciences

05/29/2026

AI in life sciences has moved past experimentation. The real challenge is putting it to work in actual workflows, with the right data, governance, validation, and guardrails.

USDM helps organizations deploy AI safely and defensibly in regulated environments — not in theory, but where the work actually happens.

Read more:

Blog post: A practical look at how Glean fits into the enterprise AI ecosystem as a governed work AI layer across knowledge, permissions, assistants, agents, and workflows.

05/29/2026

In life sciences, one wrong AI move can mean a failed audit or a delayed product launch.
USDM Life Sciences — 25 years of regulated expertise, now purpose-built for AI governance.
→ https://www.usdm.com/resources/white-papers/ai-governance-for-life-sciences-enterprise-framework

05/28/2026

Life sciences teams don’t need “more AI.” They need governed, permission-aware knowledge access that can support real regulated work.

USDM’s partnership with Glean helps organizations connect enterprise knowledge, strengthen traceability, and move from AI intent to measurable impact.

Read more:

Blog post: Why USDM chose Glean as a Work AI partner for life sciences — enterprise search, permission-aware knowledge, governed connectors, and a practical path from AI intent to regulated impact.

05/28/2026

Quality teams catching deviations before auditors ask. Regulatory teams drafting faster. Every function with instant access to knowledge across Viva, SharePoint, and Box.
This is what AI actually looks like inside a life sciences team. USDM and Glean built it.
→ https://www.usdm.com/resources/blogs/usdm-puts-ai-to-work-for-life-sciences

05/27/2026

AI readiness in life sciences shouldn’t take a year — and it shouldn’t end in a binder no one uses.

USDM’s 90-day approach helps teams identify where AI can create value, where it creates regulated risk, and what operating model is needed to move safely.

Read the guide:

Blog post: A 90-day AI readiness assessment for life sciences: inventory use cases, classify risk, map data and platform controls, select pilots, and build a governed adoption roadmap.

05/27/2026

AI in life sciences is no longer a question of "if" — it's a question of "how do we govern it?"
Our white paper from USDM Life Sciences breaks down the enterprise AI governance framework leading pharma, biotech, and medical device teams use to deploy AI safely, at scale, and ready for regulatory scrutiny.
→ https://usdm.com/resources/white-papers/ai-governance-for-life-sciences-enterprise-framework

05/26/2026

AI can drive real operational impact in medical device manufacturing — when it’s built around the process, the data, and the regulatory requirements.

In this case study, USDM helped a global manufacturer use AI to reduce complaint processing backlog, support adverse event reporting goals, and cut manual resources by 75%.

Read the case study:

The only partner that governs AI AND builds it within GxP guardrails.

05/26/2026

Who's accountable when your vendor's AI fails compliance?
(Hint: it's not them.)
Your CRO, your data partners, your validation vendors — they're all running AI on your regulated workflows. When EU AI Act enforcement begins, the responsibility lands on you.
USDM Life Sciences brings continuous AI governance across your entire vendor ecosystem.
Read the case study → https://usdm.com/resources/case-studies/transforming-third-party-vendor-risk-management-at-enterprise-scale

05/22/2026

2026 is shaping up to be a defining year for AI in life sciences. EU AI Act enforcement begins, AI is showing up across validated workflows, and boards are pushing for compliance cost cuts. Most AI pilots will fail—not from bad tech, but from no governance.
USDM Life Sciences' new white paper shows you the framework leading teams are using to win. Plus, our AI Center of Excellence delivers it without the $2M internal team.
→ https://usdm.com/resources/white-papers/ai-governance-for-life-sciences-enterprise-framework

05/22/2026

21 CFR Part 11 compliance is more than a technical checkbox — it’s about proving electronic records and signatures are trustworthy, traceable, and inspection-ready.

USDM’s practical guide breaks down the core requirements life sciences teams need to manage, including audit trails, access controls, eSignatures, validation, and ongoing monitoring.

Read the guide:

Blog post: Learn how to achieve 21 CFR Part 11 compliance with secure electronic records, audit trails, eSignatures, and validation best practices for life sciences.

05/21/2026

You own one of the most powerful platforms in life sciences. So why does it still cost like a legacy system?
Validation can eat 50% of your Vault budget. And later this year, Veeva is embedding AI into GxP workflows — turning unoptimized environments into board-level risk.
USDM Life Sciences' new white paper shows how to cut TCO by up to 30%.
Read the white paper → https://usdm.com/resources/white-papers/building-ai-ready-veeva-vault-operating-model